Predicting clinical response to everolimus in ER+ breast cancers using machine-learning

Endocrine therapy remains the primary treatment choice for ER+ breast cancers. However, most advanced ER+ breast cancers ultimately develop resistance to endocrine. This acquired resistance to endocrine therapy is often driven by the activation of the PI3K/AKT/mTOR signaling pathway. Everolimus, a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nath, Aritro, Cosgrove, Patrick A., Chang, Jeffrey T., Bild, Andrea H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592823/
https://www.ncbi.nlm.nih.gov/pubmed/36304922
http://dx.doi.org/10.3389/fmolb.2022.981962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592823/
https://www.ncbi.nlm.nih.gov/pubmed/36304922
http://dx.doi.org/10.3389/fmolb.2022.981962

Ejemplares similares